Premium
Carboplatin‐induced immune hemolytic anemia
Author(s) -
Marani T. M.,
Trich M. B.,
Armstrong K. S.,
Ness P. M.,
Smith J.,
Minniti C.,
Sandler S. G.
Publication year - 1996
Publication title -
transfusion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.045
H-Index - 132
eISSN - 1537-2995
pISSN - 0041-1132
DOI - 10.1046/j.1537-2995.1996.36111297091748.x
Subject(s) - carboplatin , medicine , anemia , hemolytic anemia , immune system , hemolysis , autoimmune hemolytic anemia , immunology , chemotherapy , cisplatin
BACKGROUND: A case of acute hemolysis following therapy with carboplatin, an anticancer chemotherapeutic agent, was investigated. Hemolytic anemia has been associated with cisplatin, a related drug, but not with carboplatin. CASE REPORT: An 8‐year‐old boy was treated for an astrocytoma by monthly intravenous injections of carboplatin. Lower back pain was noted after 26 monthly injections, and overt intravascular hemolysis occurred after the 27th injection. The direct antiglobulin test was 4+ with anti‐IgG and 1+ with anti‐C3d. RESULTS: Blood samples obtained on Days 28 and 56 after the last injection were tested for carboplatin‐dependent antibody. The direct antiglobulin test was 1+ with anti‐IgG; the eluate was 1+ with and without carboplatin. The serum indirect antiglobulin test was negative in the absence of carboplatin, 3+ to 4+ in the presence of carboplatin, and 1+ with carboplatin‐coated cells. Day 56 serum antibody titer was 64 (agglutination at 37 degrees C), 512 (indirect antiglobulin test) in the presence of carboplatin, and 8 (indirect antiglobulin test) with carboplatin‐coated cells. CONCLUSION: The findings indicate a carboplatin‐induced antibody reacting in vitro by a complex mechanism combining elements of “immune complex,” drug adsorption, and autoantibody mechanisms. Drug‐dependent hemolysis is a previously unreported but potentially serious complication of carboplatin therapy.